{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-008977","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2022-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.659744+00:00","generated_at":"2026-06-27T14:27:37.135237+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Celldex amends bylaws to implement proxy access for shareholders","bullets":["Board approved proxy access on Jan 25, 2022, adding Article III Section 13 to bylaws.","Stockholders or group owning at least 3% of stock continuously for 3 years may nominate directors.","Maximum nominees is greater of 2 individuals or 20% of board, subject to requirements.","Proxy access will first apply for the 2023 annual meeting of shareholders.","Full amendment text filed as Exhibit 3.1 to this 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-008977","json":"https://secwatch.observer/filing/0001104659-22-008977.json","markdown":"https://secwatch.observer/filing/0001104659-22-008977.md","text":"https://secwatch.observer/filing/0001104659-22-008977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000110465922008977/0001104659-22-008977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000110465922008977/tm224432d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T14:27:37.135237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}